Supreme People’s Court of China [2023]: Yangtze River Pharmaceutical Group v HIPI Pharma Tech,
WIPO Lex
AtrásFecha de la sentencia25 de mayo de 2023Órgano emisorSupreme People’s Court of the People’s Republic of ChinaInstanciaInstancia FinalTipo de procedimientoJudicial (Civil)MateriaCompetencia, Patentes (Invenciones)Parte demandante/recurrenteYangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd; Yangtze River Pharmaceutical Group Co., Ltd.Parte demandadaHefei Industrial Pharmaceutical Institute Co., Ltd; Hefei Enrite Pharmaceutical Co., Ltd.Palabras clave
Patent,
Abuse of dominant market position,
Restricting dealing,
Unfairly high price
Sentencia/ResoluciónInglésSupreme People’s Court of China [2023]: Yangtze River Pharmaceutical Group v HIPI Pharma Tech HTMLResumenInglésSupreme People’s Court of China [2023]: Yangtze River Pharmaceutical Group v HIPI Pharma Tech HTMLN° WIPO LexWIPOLEX016-j